Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

IntroductionLoss of B-cell aplasia (BCA) is a well-known marker of functional loss of CD19 CAR-T. Most relapses and loss of BCA occur in the first months after CD19 CAR-T infusion. In addition, high tumor burden (HTB) has shown to have a strong impact on relapse, especially in CD19-negative. However...

Full description

Bibliographic Details
Main Authors: Águeda Molinos-Quintana, Anna Alonso-Saladrigues, Blanca Herrero, Teresa Caballero-Velázquez, Víctor Galán-Gómez, Melissa Panesso, Montserrat Torrebadell, Javier Delgado-Serrano, Concepción Pérez de Soto, Anna Faura, Berta González-Martínez, Ana Castillo-Robleda, Cristina Diaz-de-Heredia, Antonio Pérez-Martínez, José María Pérez-Hurtado, Susana Rives, José Antonio Pérez-Simón
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
B cell aplasia
late B-cell recovery
pre-infusion tumor burden
CD19 CART-cells
relapsed/refractory acute lymphoblastic leukemia
tisagenlecleucel
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1280580/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1280580/full

Similar Items